Valeant Pharma (VRX) Short Interest Surges 56% - Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging
April 11, 2016 8:02 AM EDTLAVAL, Quebec, April 11, 2016 /PRNewswire/ --Â Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today issued the following statement regarding the Senate Committee on Aging's subpoena to depose Valeant Chief Executive Officer, J. Michael Pearson:
"The Board has requested Mr. Pearson's cooperation in connection with a subpoena for deposition from the Senate Committee on Aging prior to the Committee's scheduled April 27 hearing. Â The Board understands that Mr. Pearson is in dialogue with the Senate Committee on Aging regarding his deposition and that those discussions are ongoing."
About Valeant
Valeant... More
